Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer. Sci Rep (2017) 1.40

Triple negative breast cancer: the kiss of death. Oncotarget (2017) 0.78

Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. Nat Rev Clin Oncol (2016) 0.78

Adaptive immunity programmes in breast cancer. Immunology (2016) 0.77

Germline Mutations in Triple-Negative Breast Cancer. Breast Care (Basel) (2017) 0.76

RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. Oncotarget (2016) 0.76

Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer. Mol Biosyst (2016) 0.76

Ziyuglycoside I Inhibits the Proliferation of MDA-MB-231 Breast Carcinoma Cells through Inducing p53-Mediated G2/M Cell Cycle Arrest and Intrinsic/Extrinsic Apoptosis. Int J Mol Sci (2016) 0.76

Post-nano strategies for drug delivery: Multistage porous silicon microvectors. J Mater Chem B Mater Biol Med (2016) 0.75

Resistin potentiates chemoresistance and stemness of breast cancer cells: Implications for racially disparate therapeutic outcomes. Cancer Lett (2017) 0.75

Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP). PLoS One (2017) 0.75

The fate of BRCA1-related germline mutations in triple-negative breast tumors. Am J Cancer Res (2017) 0.75

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord (2017) 0.75

Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data. Oncotarget (2016) 0.75

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers (Basel) (2017) 0.75

Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep (2017) 0.75

Tumor-Specific Peptide, Selected from a Phage Peptide Library, Enhances Antitumor Activity of Lactaptin. PLoS One (2016) 0.75

Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study. Chin J Cancer Res (2016) 0.75

P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. PLoS One (2017) 0.75

Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast Cancer. Sci Rep (2017) 0.75

Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. Breast Cancer Res (2017) 0.75

Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency. PLoS Genet (2017) 0.75

Small-molecule RL71-triggered excessive autophagic cell death as a potential therapeutic strategy in triple-negative breast cancer. Cell Death Dis (2017) 0.75

CHST9 rs1436904 genetic variant contributes to prognosis of triple-negative breast cancer. Sci Rep (2017) 0.75

Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis. Oncotarget (2017) 0.75

Peri-foci adipose-derived stem cells promote chemoresistance in breast cancer. Stem Cell Res Ther (2017) 0.75

Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer. J Steroid Biochem Mol Biol (2016) 0.75

Identification of candidate genes associated with triple negative breast cancer. Genes Cancer (2017) 0.75

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol (2017) 0.75

Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov (2017) 0.75

Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. Oncotarget (2017) 0.75

Molecular portraits of human breast tumours. Nature (2000) 94.14

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39

The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47

Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13

Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79

Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol (2003) 12.48

The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56

Triple-negative breast cancer. N Engl J Med (2010) 11.39

The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49

Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (2014) 9.66

HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (2012) 8.74

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48

Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell (1997) 8.28

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12

Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95

Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91

Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00

Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61

Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45

Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res (2009) 6.43

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34

Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82

The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res (2008) 5.69

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol (2013) 5.67

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49

Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81

The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76

Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72

The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem (2000) 4.49

Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (2009) 4.47

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41

An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33

S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood (2002) 4.27

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol (2014) 4.27

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17

Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16

Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol (2014) 4.06

Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98

BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene (2006) 3.91

CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature (2009) 3.88

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol (2014) 3.80

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol (2014) 3.80

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77

Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem (2004) 3.64

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol (2014) 3.15

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol (2008) 3.09

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J (2008) 2.95

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov (2012) 2.89

A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res (2009) 2.84

Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res (2000) 2.81

Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res (2010) 2.77

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2014) 2.75

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst (2004) 2.72

Precision medicine--personalized, problematic, and promising. N Engl J Med (2015) 2.67

Basal-like breast cancer and the BRCA1 phenotype. Oncogene (2006) 2.62

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55

Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res (2006) 2.52

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol (2012) 2.50

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol (2010) 2.49

The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst (2004) 2.49

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol (2014) 2.45

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45

Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci (2004) 2.33

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30